Pharmaceutical markets and insurance worldwide:
The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government pla...
Saved in:
| Format: | Electronic eBook |
|---|---|
| Language: | English |
| Published: |
Bingley, U.K.
Emerald
2010
|
| Series: | Advances in health economics and health services research
v. 22 |
| Subjects: | |
| Online Access: | DE-634 DE-1043 DE-M347 DE-523 DE-91 DE-473 DE-19 DE-355 DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 DE-1046 Volltext |
| Summary: | The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries |
| Physical Description: | 1 Online-Ressource (xxi, 344 Seiten) ill |
| ISBN: | 9781849507172 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV048845882 | ||
| 003 | DE-604 | ||
| 005 | 20240104 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 230306s2010 xx a||| o|||| 00||| eng d | ||
| 020 | |a 9781849507172 |c £82.95 ; €121.95 ; $154.95 |9 978-1-84950-717-2 | ||
| 024 | 7 | |a 10.1108/S0731-2199(2010)22 |2 doi | |
| 035 | |a (ZDB-1-EPB)bslw07266466 | ||
| 035 | |a (DE-599)BVBBV048845882 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-634 |a DE-1043 |a DE-M347 |a DE-523 |a DE-91 |a DE-473 |a DE-19 |a DE-355 |a DE-703 |a DE-20 |a DE-706 |a DE-824 |a DE-29 |a DE-739 |a DE-1046 | ||
| 245 | 1 | 0 | |a Pharmaceutical markets and insurance worldwide |c edited by Avi Dor |
| 264 | 1 | |a Bingley, U.K. |b Emerald |c 2010 | |
| 300 | |a 1 Online-Ressource (xxi, 344 Seiten) |b ill | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Advances in health economics and health services research |v v. 22 | |
| 505 | 8 | |a ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood | |
| 505 | 8 | |a ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- | |
| 505 | 8 | |a Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon -- | |
| 520 | 3 | |a The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries | |
| 650 | 7 | |a Business & Economics |2 General | |
| 650 | 7 | |a Business & Economics |2 Insurance | |
| 650 | 4 | |a Health economics | |
| 650 | 7 | |a Medical |2 Pharmacology | |
| 650 | 4 | |a Health insurance | |
| 650 | 4 | |a Pharmaceutical industry | |
| 700 | 1 | |a Dor, Avi |d 1956- |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-1-EPB | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-034111222 | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-634 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-1043 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-M347 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-523 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-91 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-473 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-19 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-355 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-703 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-20 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-706 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-824 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-29 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-739 |p ZDB-1-EPB |x Verlag |3 Volltext | |
| 966 | e | |u https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |l DE-1046 |p ZDB-1-EPB |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1821342600181841920 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| building | Verbundindex |
| bvnumber | BV048845882 |
| collection | ZDB-1-EPB |
| contents | ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon -- |
| ctrlnum | (ZDB-1-EPB)bslw07266466 (DE-599)BVBBV048845882 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV048845882</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240104</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">230306s2010 xx a||| o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849507172</subfield><subfield code="c">£82.95 ; €121.95 ; $154.95</subfield><subfield code="9">978-1-84950-717-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1108/S0731-2199(2010)22</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-1-EPB)bslw07266466</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048845882</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-634</subfield><subfield code="a">DE-1043</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-523</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-1046</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical markets and insurance worldwide</subfield><subfield code="c">edited by Avi Dor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bingley, U.K.</subfield><subfield code="b">Emerald</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xxi, 344 Seiten)</subfield><subfield code="b">ill</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Advances in health economics and health services research</subfield><subfield code="v">v. 22</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg --</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon --</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Business & Economics</subfield><subfield code="2">General</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Business & Economics</subfield><subfield code="2">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health economics</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical</subfield><subfield code="2">Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dor, Avi</subfield><subfield code="d">1956-</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-EPB</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034111222</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-634</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-1043</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-M347</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-523</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-91</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-473</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-19</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-703</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-20</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-706</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-824</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-29</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-739</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22</subfield><subfield code="l">DE-1046</subfield><subfield code="p">ZDB-1-EPB</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV048845882 |
| illustrated | Illustrated |
| index_date | 2024-07-03T21:39:04Z |
| indexdate | 2025-01-15T19:00:59Z |
| institution | BVB |
| isbn | 9781849507172 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034111222 |
| open_access_boolean | |
| owner | DE-634 DE-1043 DE-M347 DE-523 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 DE-1046 |
| owner_facet | DE-634 DE-1043 DE-M347 DE-523 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 DE-1046 |
| physical | 1 Online-Ressource (xxi, 344 Seiten) ill |
| psigel | ZDB-1-EPB |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Emerald |
| record_format | marc |
| series2 | Advances in health economics and health services research |
| spelling | Pharmaceutical markets and insurance worldwide edited by Avi Dor Bingley, U.K. Emerald 2010 1 Online-Ressource (xxi, 344 Seiten) ill c rdamedia cr rdacarrier Advances in health economics and health services research v. 22 ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon -- The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries Business & Economics General Business & Economics Insurance Health economics Medical Pharmacology Health insurance Pharmaceutical industry Dor, Avi 1956- Sonstige oth https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Pharmaceutical markets and insurance worldwide ch. 13. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie, William R. Doucette -- ch. 14. Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla, Neeraj Sood ch. 7. Does prescription drug adherence reduce hospitalizations and costs? : the case of diabetes / William E. Encinosa, Didem Bernard, Avi Dor -- ch. 8. Cost sharing, benefit design, and adherence : the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants, Jane Castelli-Haley -- ch. 9. Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin, Dean G. Smith -- ch. 10. Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? / Jie Chen, John A. Rizzo -- ch. 11. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- ch. 12. The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Overview / Avi Dor -- ch. 1. Pharmaceutical policies in European countries / Pedro Pita Barros -- ch. 2. International experience with comparative effectiveness research : case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist, Axel C. Mühlbacher -- ch. 3. Pharmaceutical policy in the Netherlands : from price regulation toward managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut, Marco Varkevisser -- ch. 4. Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax, Amir Shmueli -- ch. 5. Global budgets and provider incentives : hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien, Jing Hua Zhang -- ch. 6. Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley, Kosali Simon -- Business & Economics General Business & Economics Insurance Health economics Medical Pharmacology Health insurance Pharmaceutical industry |
| title | Pharmaceutical markets and insurance worldwide |
| title_auth | Pharmaceutical markets and insurance worldwide |
| title_exact_search | Pharmaceutical markets and insurance worldwide |
| title_exact_search_txtP | Pharmaceutical markets and insurance worldwide |
| title_full | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_fullStr | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_full_unstemmed | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_short | Pharmaceutical markets and insurance worldwide |
| title_sort | pharmaceutical markets and insurance worldwide |
| topic | Business & Economics General Business & Economics Insurance Health economics Medical Pharmacology Health insurance Pharmaceutical industry |
| topic_facet | Business & Economics Health economics Medical Health insurance Pharmaceutical industry |
| url | https://www.emerald.com/insight/publication/doi/10.1108/S0731-2199(2010)22 |
| work_keys_str_mv | AT doravi pharmaceuticalmarketsandinsuranceworldwide |